Severe Combined Immunodeficiency Disease (SCID)

Call for an Appointment

Duke Children's is one of 44 programs in the U.S. and Canada that treat infants born with severe combined immunodeficiency (SCID). We have achieved an overall survival rate of 75 percent for these infants using innovative bone marrow stem cell transplant therapies that do not require pre-transplant chemotherapy.